Sanofi nabs long-sought FDA approval for daily GLP-1 contender Adlyxin - FiercePharma

FiercePharma

Sanofi nabs long-sought FDA approval for daily GLP-1 contender Adlyxin FiercePharma Sanofi(SNY) finally won FDA approval of its long-awaited GLP-1 diabetes drug lixisenatide, to be sold in the U.S. as Adlyxin. But “finally” is the operative word. After years of delay, the once-daily Adlyxin will hit the U.S. market as Eli Lilly's ... GLP-1 Agonist Lixisenatide (Adlyxin) Okayed for Type 2 Diabetes in USMedscape FDA approves Adlyxin to treat type 2 diabetesFDA.gov Sanofi Receives FDA Approval of Adlyxin™ for Treatment of Adults with Type 2 DiabetesPR Newswire (press release) Healio -MedPage Today -MD Magazine -Managed Care magazine all 22 news articles »

Sanofi nabs long-sought FDA approval for daily GLP-1 contender Adlyxin - FiercePharma
Read More